Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$5.86 USD
+0.19 (3.26%)
Updated Jul 9, 2024 04:00 PM ET
Pre-Market: $5.95 +0.10 (1.62%) 8:24 AM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HUMA 5.86 +0.19(3.26%)
Will HUMA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUMA
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
Should You Buy Humacyte (HUMA) Ahead of Earnings?
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
Other News for HUMA
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
Peering Into Humacyte's Recent Short Interest
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
Humacyte presents positive preclinical data for BVP program
3 Best Stocks to Buy Now, 6/18/2024, According to Top Analysts